PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.
The 23rd Annual NewsMakers in the Biotech Industry – New York, September 9, 2016
September 9, 10:00 a.m. EDT – Christopher Anzalone, Ph.D., Arrowhead president and CEO will deliver a corporate presentation
7th Non-Coding RNA & RNAi Therapeutics Conference – Boston, September 14-15, 2016
September 14, 4:30 p.m. EDT – Erik Bush, Ph.D., Arrowhead director of extrahepatic targeting will deliver an oral presentation titled, “Targeted delivery strategies using Dynamic PolyconjugateTM (DPCTM) technology”
2016 International HBV Meeting – Seoul, Korea, September 21-24, 2016
September 24, 8:30 a.m. KST – Zhao Xu, Ph.D., Arrowhead senior scientist will deliver an oral presentation titled, “Functional HBsAg-encoding HBV fusion transcripts are produced from integrated HBV DNA in chronically infected chimpanzees - evidence from single molecule, real time (SMRT) sequencing”
Copies of presentation materials and webcasts can be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after each presentation is delivered.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.